David Bridges
Elizabeth Holmes, the controversial founder of Theranos, is currently serving a lengthy sentence of 11 years in prison due to her involvement in deceiving investors with her fraudulent blood testing startup. Her partner, who shares two children with her, is now ambitiously seeking to raise $50 million for a new venture in the same healthcare technology space. This situation raises eyebrows and questions about the ethics and future of diagnostic technology.
Initially met with skepticism, the internet’s reaction to this news was filled with disbelief, as many thought it could only be satire or a hoax. However, reports from the New York Times confirmed that this story is very much real. The partner, Billy Evans, has founded a company named Haemanthus, which is named after a species of flower known as the blood lily. The company promotes itself as “the future of diagnostics” and boasts “a radically new approach to health testing,” which sounds strikingly similar to the original claims made by Theranos.
It’s intriguing to consider why Evans, who is described by the Times as an heir to a substantial hotel fortune, would choose to enter the blood-testing industry. One might speculate that perhaps it’s due to the family’s history in business, or maybe he sees an opportunity in a market still recovering from the fallout of Theranos. Regardless of his motivations, the decision to pursue this venture raises numerous questions about the future of healthcare diagnostics.
Mashable Light Speed
According to unnamed sources cited by NPR, Evans has reportedly “raised millions” so far, primarily from friends, family, and other supporters. The ambitious plans for Haemanthus include an initial focus on testing pets for various diseases before transitioning to human diagnostics. This strategy raises eyebrows and could either mark a true innovation in the field or repeat the mistakes of prior ventures.
The absurdity of this entire situation has left many internet users in disbelief. A user on Bluesky humorously remarked on the headline, needing to clarify that the story was not a product of artificial intelligence or a mere joke. The community’s reaction highlights the ongoing skepticism surrounding the world of health-tech startups, especially those with a controversial past.
As expected, the internet has responded with a plethora of jokes and memes about Evans‘ startup. Social media has become a playground for satire, where users share their humorous takes on the situation, reflecting both disbelief and a sense of amusement at the absurdity of the circumstances surrounding Theranos and its legacy.
In an era characterized by bizarre and unbelievable headlines, it’s truly remarkable that the news continues to surprise us. The unfolding tales of Theranos and its aftermath serve as a reminder of the volatility in the healthcare innovation sector, where the promise of groundbreaking technology can easily blur into deception.
var facebookPixelLoaded = false;
window.addEventListener(‘load’, function(){
document.addEventListener(‘scroll’, facebookPixelScript);
document.addEventListener(‘mousemove’, facebookPixelScript);
})
function facebookPixelScript() {
if (!facebookPixelLoaded) {
facebookPixelLoaded = true;
document.removeEventListener(‘scroll’, facebookPixelScript);
document.removeEventListener(‘mousemove’, facebookPixelScript);
!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function(){n.callMethod?
n.callMethod.apply(n,arguments):n.queue.push(arguments)};if(!f._fbq)f._fbq=n;
n.push=n;n.loaded=!0;n.version=’2.0′;n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
document,’script’,’//connect.facebook.net/en_US/fbevents.js’);
fbq(‘init’, ‘1453039084979896’);
fbq(‘track’, “PageView”);
}
}
Daniel Mercer
Brandon Fletcher
